Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX-474 for diffuse cutaneous systemic sclerosis
2025-523288-39-00Phase 2Authorised
- Sponsor
- Mediar Therapeutics
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in diffuse cutaneous systemic sclerosis (dcSSc) comparing MTX-474 with Placebo (2 arms). Primary endpoint: Mean change from baseline to Week 24 in modified Rodnan skin score. Planned start Oct 2026; status: authorised.
02
Drugs
MTX-474
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on 2025-523288-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523288-39-00.